Global technological trends in sustainable antimicrobial surface formulations: a patent-based review for cleaner healthcare environments Authors: Luana Conte Nunes, Stéfanno Souza Santos, Luana Rossato, Izabel Almeida Alves, Edith Cristina Laignier Cazedey Published: 2026 ABSTRACT AbstractIntroductionHealthcare-associated infections (HAIs) are a global challenge, exacerbated by multidrug-resistant pathogens. This study systematically maps antimicrobial surface formulations (1995–2024), analyzing gaps in regulatory readiness, toxicological validation, and sustainability.Areas coveredUsing the Espacenet database and PRISMA guidelines, 49 patents were analyzed. Innovation surged post-2015, led by private corporations (72.09%) in the USA, Canada, and China (67.35%). Synthetic actives, primarily quaternary ammonium compounds, dominated (71.43%), while natural (16.33%) and hybrid (10.20%) approaches were less frequent. Key targets included S. aureus, K. pneumoniae, and E. coli. Although 38.77% of patents claimed sustainability (biodegradability/low toxicity), only 40.82% disclosed mechanisms of action, and 34.69% provided toxicological data.Expert opinionA significant gap exists between technological innovation and regulatory/safety validation. Future developments must integrate life-cycle assessments and robust toxicological testing. Harmonized regulatory pathways and public–private partnerships are essential to translate these innovations into scalable, sustainable, and safer disinfectant solutions for healthcare environments.Keywords: Sanitizers, health, infections, microorganisms, technology, gaps and trends Introduction Healthcare-associated infections (HAIs) remain a major global public health threat, contributing significantly to morbidity, mortality, and healthcare costs. Of particular concern is the growing prevalence of multidrug-resistant organisms, including the emerging fungus Candida auris and bacterial pathogens such as Klebsiella pneumoniae and Acinetobacter baumannii, which severely limit therapeutic options and complicate infection control strategies [1]. Inadequate environmental hygiene in hospitals contributes to pathogen persistence on surfaces, elevating risks for vulnerable patients and healthcare workers [2–4]. This underscores the urgent need for advanced disinfectant technologies that are both effective and sustainable. Disinfectants are essential for infection prevention, yet many conventional agents raise concerns due to their toxicity, resistance induction, and environmental impact [5,6]. Traditional compounds, such as quaternary ammonium compounds, oxidizing agents, and halogenated phenols, while effective, can have residual effects on ecosystems and human health, especially with chronic exposure [7,8]. Recent studies have shown that quaternary ammonium compounds (QACs) are consistently present in nearly 100% of samples, with concentrations in wastewater ranging from <1 µg/L to 1200 µg/L, depending on the matrix. Such widespread contamination raises critical concerns due to their persistence in the environment (weeks to months), potential for bioaccumulation, and ability to promote antimicrobial resistance through mechanisms such as efflux pump activation, underscoring the urgent need for sustainable disinfectant innovations [9,10]. Emerging innovations in disinfectant formulations increasingly emphasize sustainability, including the use of biodegradable ingredients, biosurfactants, plant-derived antimicrobials, and hybrid systems designed to reduce environmental toxicity and microbial resistance [11,12]. These environmental and public health concerns have been driving the search for disinfectant innovations that prioritize sustainability. These strategies align with Sustainable Development Goals (SDGs), particularly SDG 3 (Good Health and Well-being) and SDG 12 (Responsible Consumption and Production) [13]. However, beyond the scientific literature, it is essential to map which of these innovations are actually advancing toward industrial development and commercialization. Patent-based technological prospecting is a powerful tool for mapping innovation dynamics, identifying leading actors, and uncovering gaps in market-ready solutions [14]. Unlike scientific publications, which often focus on conceptual or preliminary findings, patents reflect a closer step toward industrial application and commercialization, making them valuable indicators of innovation readiness [15–17]. Globally, patents serve as a central channel for disclosing technological knowledge. Empirical evidence shows that a substantial proportion of innovations in the chemical and pharmaceutical industries are first disclosed through patents, making them a powerful metric for technological forecasting [18,19]. In Europe, for example, the propensity to patent innovations averages 35.9% for products and 24.8% for processes, but exceeds 50% in sectors such as pharmaceuticals and chemicals [18]. More recent studies reinforce the view that patents are not only appropriation tools but also selective mechanisms for knowledge disclosure with significant spillover effects for competitors and markets [20,21]. This approach has been successfully applied in green chemistry and renewable energy fields, where patent data are used to anticipate market trends, guide R&D priorities, and support investment decisions [16]. Unlike previous reviews that focused exclusively on scientific literature or clinical efficacy, often neglecting innovation pipelines, commercialization readiness, and sustainability claims, patent-based analysis is uniquely suited to map technologies closer to industrial application. Accordingly, this is the first global patent-based study to explore antimicrobial surface disinfectants from both technological and environmental perspectives. This study systematically reviews 49 international patents published between 1995 and 2024 related to antimicrobial surface formulations (see Supplementary Tables S1–S3 for the complete dataset, toxicological and microbiological testing, and sustainability claims). By analyzing formulation strategies, active compounds, modes of action, and claimed benefits, this review seeks to illuminate technological pathways that support cleaner production and safer healthcare environments while identifying challenges to effective implementation and global accessibility. This dual approach identifies emerging trends and market drivers and highlights gaps in regulatory compliance, toxicological validation, and global accessibility, providing actionable insights for policymakers, researchers, and industry stakeholders. Methods Although the PRISMA 2020 statement was originally designed for clinical systematic reviews, its structured and transparent phases (identification, screening, eligibility, and inclusion) are highly suitable for systematizing patent database searches. We adapted the PRISMA framework to patent data, modifying eligibility criteria to suit patent documents, as detailed below, while maintaining the principles of reproducibility and bias reduction. We also referenced established technological prospecting methodologies to complement methodological rigor. This systematic review followed the PRISMA 2020 (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines [22] to ensure transparency and reproducibility in the screening and analysis of patent data. The study used the Espacenet Patent Search platform (https://worldwide.espacenet.com) and focused on patents published between January 1, 1995, and November 11, 2024. The search strategy employed the keywords “formulation” AND “antimicrobial” using Boolean operators across the title, abstract, and full-text fields. Language filters were applied to include only English, Spanish, or Portuguese, ensuring accessibility for full-text evaluation. To target disinfectants relevant to healthcare environments, the search was restricted to two specific International Patent Classification (IPC) codes, A01N33/12, which covers quaternary ammonium compounds and related disinfectants, commonly used in hospital-grade sanitizers, and A01P1/00, which encompasses non-therapeutic antimicrobial agents designed for external application. These IPC codes were selected as they are the most specific and directly related to hospital-grade surface disinfectants. However, we recognize that this restriction may exclude patents classified only under other codes (e.g., nanomaterials, coatings), potentially introducing a selection bias, which is acknowledged as a limitation. Eligible patents explicitly describe antimicrobial formulations for external use on inanimate surfaces in healthcare or hygiene settings, including hospitals, clinics, outpatient facilities, long-term care centers, and food preparation areas. Patents were required to have an accessible technical description with sufficient technical data, defined as describing at least the formulation composition and one or more target microorganisms. Patents were excluded if they were related solely to internal use (e.g., oral or injectable formulations); focused on agriculture, veterinary medicine, or industrial processing; or were written in non-analyzable languages such as Mandarin or German. The patent exclusion in Mandarin and German was necessary because the review team lacked technical proficiency in these languages to ensure accurate and reliable data extraction. We acknowledge that this introduces a language bias and may lead to underrepresentation of innovations from countries such as China and Germany, a limitation explicitly recognized in the discussion. The initial search retrieved 124 records. After removing duplicates, 120 records were screened based on title and abstract. Of these, 65 patents were excluded for failing to meet the eligibility criteria. A total of 55 patents were assessed through full-text review, and an additional 6 patents were excluded due to language barriers or insufficient technical data. Ultimately, 49 patents were included for detailed qualitative synthesis (Figure 1). PRISMA flow diagram summarizing the identification, screening, and inclusion of patents reviewed in this study. For each eligible patent, key data were extracted systematically, including the type of active compound (synthetic, natural, hybrid, enzymatic); claimed mechanism of action (bactericidal, fungicidal, virucidal); presence of toxicological and microbiological testing; sustainability attributes, such as biodegradability, low toxicity, or plant-based origin; and filing country and type of applicant (industry, academia, or individual inventor). All collected data were analyzed using descriptive statistics (absolute and relative frequencies, temporal distribution, and geographical mapping). While temporal trends were observed (e.g., increase post-2015), no formal statistical tests (e.g., Poisson regression or Mann-Kendall) were applied due to the sample size (n = 49) and the exploratory-descriptive nature of the study. Statistical analyses and visualizations were performed using R version 4.3.2 and Microsoft Excel 365, enabling the identification of temporal trends, geographical concentration, and technological classes. Supplementary Tables S1–S3 present the complete dataset, including details on toxicological and microbiological testing (Table S2) and sustainability-related claims (Table S3). Sustainability attributes were categorized as follows: (1) Biodegradability: explicit claim of degradation by microorganisms; (2) Plant-based origin: mention of extracts, essential oils, or plant derivatives; (3) Low toxicity: claim of reduced toxicity to humans or non-target organisms; (4) Green synthesis: use of ecological solvents, catalysts, or reaction conditions. The absence of quantitative metrics (e.g., carbon footprint and ecotoxicity indices) was identified as a gap. To ensure the reliability and validity of the findings, two reviewers with expertise in pharmaceutical sciences and patent analysis independently conducted the data extraction. Any discrepancies were resolved through discussion and, when necessary, adjudicated by a third senior reviewer. This multi-step review process minimized bias and enhanced the accuracy of the dataset, strengthening the robustness of the conclusions drawn from this study. Results and discussion General overview and temporal trends The analysis of the 49 selected patents revealed a marked acceleration of technological activity in antimicrobial surface formulations over the past decade. Between 1995 and 2014, only 19 patents (38.78%) were filed, whereas 30 patents (61.22%) were registered from 2015 to 2024, reflecting an increase of more than 50% in innovation output during this period. This surge coincides with the growing global awareness of antimicrobial resistance and the emergence of multidrug-resistant organisms, particularly Candida auris and carbapenem-resistant Enterobacteriaceae [23,26]. As shown in Figure 2, the steepest growth was observed between 2017 and 2021, a period marked by increased regulatory scrutiny and the COVID-19 pandemic, which heightened demand for effective disinfectants. These findings may suggest a pattern in which innovation responds to external drivers, a characteristic not unique to this sector, as many technology fields exhibit similar crisis-responsive dynamics. However, given the modest sample size (n = 49), this interpretation should be considered preliminary, and future studies with larger patent sets are needed to confirm these trends. Small absolute changes can produce large relative differences over 30 years, necessitating cautious interpretation of percentage-based findings. Number of patents related to antimicrobial surface formulations published annually from 1995 to 2024. Geographic and institutional distribution The geographic distribution of patents highlights substantial inequalities in innovation capacity. High-income countries dominated filings, with the United States (36.73%, n = 18), Canada (16.33%, n = 8), and China (14.29%, n = 7) collectively accounting for 67.35% of all patents (Figure 3). In contrast, Latin America and Africa were severely underrepresented, with only one patent identified from Mexico and none from African nations. Geographic distribution of the 49 antimicrobial surface formulation patents included in the review. The underrepresentation of low- and middle-income countries in patent filings may also reflect differences in intellectual property frameworks and innovation strategies. In many African and Latin American countries, “open” innovation models, traditional knowledge, and non-patented technologies may play a more significant role in infection control than formal patenting. Additionally, the costs and complexity of international patent filing (e.g., PCT applications) may be prohibitive for individual inventors or small enterprises in these regions, favoring alternative dissemination pathways. This disparity reflects differences in research infrastructure and gaps in policy and funding mechanisms that support innovation in healthcare-related technologies. Countries with the highest burden of HAIs often lack the intellectual property (IP) frameworks and R&D investments needed to develop and commercialize novel disinfectants [25,40]. These results emphasize the urgent need for international cooperation and public policies that foster equitable access to innovation, particularly through technology transfer and capacity-building initiatives. From an institutional perspective, private corporations were the dominant actors, holding 72.09% (n = 35) of patents. Key players included BASF SE, Ecolab Inc., and Procter & Gamble, underscoring the market relevance of hospital-grade sanitizers. Academia and individual inventors contributed modestly, with 6.98% (n = 4) each, though these patents frequently introduced biotechnological and plant-based innovations with high sustainability potential. This imbalance suggests that commercial interests primarily drive corporate innovation, whereas academic contributions may serve as catalysts for disruptive and sustainable alternatives. A closer review of the corporate patents reveals that most focus on incremental improvements to QAC and biguanide-based formulations, with less than 10% introducing novel mechanisms or fully biodegradable platforms. Origin and composition The majority of patents (71.43%, n = 35) relied exclusively on synthetic active ingredients, with quaternary ammonium compounds (QACs) being the most prevalent, followed by biguanides, halogenated phenols, and peroxides (Figure 4). While these compounds provide broad-spectrum antimicrobial activity, they pose environmental and public health risks, including persistence in aquatic ecosystems and the potential to contribute to antimicrobial resistance (see section 3.4 for a detailed discussion of resistance mechanisms) [8,27]. Frequency of active compound types used in antimicrobial surface formulation patents. Legend: QACs—Quaternary Ammonium Compounds. The persistent dominance of QACs in patent filings, despite well-documented environmental and resistance concerns, can be attributed to several interrelated factors. First, QACs benefit from established regulatory pathways and decades of safety data, which reduce the perceived risk and cost of market entry for manufacturers. Second, their broad-spectrum activity and chemical stability make them versatile across multiple applications (e.g., hard surfaces, medical devices, textiles). Third, the manufacturing infrastructure for QACs is highly optimized, resulting in lower production costs compared to most natural or hybrid alternatives. However, this “lock-in” effect creates a paradox: the very features that make QACs commercially attractive, regulatory familiarity, low cost, and versatility, also perpetuate reliance on chemistries that may not align with long-term sustainability goals. Breaking this cycle will require not only technological innovation but also regulatory reforms, such as expedited review pathways for biodegradable alternatives or environmental impact fees that internalize the external costs of persistent compounds. Natural actives were underrepresented, appearing in only 16.33% (n = 8) of patents, while hybrid systems combining synthetic and natural agents accounted for 10.20% (n = 5). These approaches, which included biosurfactants, essential oils, and chitosan derivatives, align more closely with the principles of green chemistry and offer advantages such as biodegradability, lower toxicity, and potential for local production [28,29]. Despite the diversity of compounds, 40.82% of patents failed to describe their mechanism of action, limiting scientific understanding and regulatory assessment. Among those reporting mechanisms, protein denaturation and membrane destabilization were the most frequently cited modes of action. This lack of transparency raises concerns regarding regulatory readiness and the ability to predict long-term ecological impacts. Frequency of microorganisms and mechanisms of action This subsection presents the microorganisms most frequently targeted by the patented formulations, followed by an interpretation of the clinical and resistance implications. This study identified the microorganisms most frequently targeted for elimination using sanitizers developed through patent publications, as shown in Figure 5 and Table 1. Frequency of microorganisms in antimicrobial surface formulation patents. Abbreviations: A. niger—Aspergillus niger; C. albicans—Candida albicans; E. Coli—Escherichia coli; K. pneumoniae—Klebsiella pneumoniae; P. aeruginosa—Pseudomonas aeruginosa; ssp—species; S. aureus—Staphylococcus aureus. Table 1.Patent groups in Figure 5.GroupPatents1US2023105226A1, US2012157540A1, US2010240762A1, CA3140688A1, CN104430526A, CN104430526B, AU2021342844A1, WO2021107870A1, US2024172759A1, WO2014177530A1, EP3613861A1, CN102845512A, CA2578282A1, CA2578282C. MX2010009312A, US2011033406A1, US2017231220A1, EP2964208A1, EP2964208A4, EP2964208B1, AU2021104043A4, MX2015017439A.2US2020245616A1, US2023105226A1, CA2720738A1, CA2720738C, US2012157540A1, CA2190839A1, US2010240762A1, CA3140688A1, CN104430526A, CN104430526B, AU2021342844A1, WO2021107870A1, EP4398725A1, US12075788B2, US2022322681A1, WO2023089126A1, US2010317640A1, US2024172759A1, WO2014177530A1, CN102845512A, CA3157901A1, CA2578282A1, CA2578282C, DE102005053926B3, AU2021104043A4, MX2015017439A.3GB2626064A; AU2021342844A1; MX2010009312A; US2023105226A1; WO2014177530A1.4US2023105226A1; US202120240762A1; CN104430526B; CN1895672A; CN21895672B; WO2021107870A1; US2024172759A1;WO2014177530A1; US2011033406A1.5P3613861A1, EP2964208A1, EP2964208A4, EP2964208B1, MX2015017439A, US2010240762A1, CA3157901A1, DE102005053926B3, WO2014177530A1, EP3613861A1, CA3157901A1, AU2021104043A4, AU2021342844A1, US2024182940A1.6EP4398725A1; US202310317640A1; WO2014177530A1; EP3613861A1; US2017231220A1.7US2020245616A1, US2023105226A1, CA2720738A1, CA2720738G, CA2190839A1, AU2021342844A1, WO2014177530A1, EP3613861A1, US2017231220A1, EP2964208A1, EP2964208A4, EP2964208B1, MX2015017439A.8US2020245616A1, US2010240762A1, AU2021342844A1, WO2021107870A1, WO2014177530A1, EP3613861A1, CA3157901A1, MX2010009312A, US2011033406A1, US2017231220A1, AU2021104043A4, MX2015017439A. Patent groups in Figure 5. The high frequency of S. aureus, K. pneumoniae, and E. coli among targeted pathogens reflects their established role in healthcare-associated infections. However, the lack of emerging microorganisms among the most frequently cited remains a concern, as they are generating more resistance mechanisms each year. Prolonged exposure of microorganisms to disinfectants can lead to adaptability and tolerance to the products [31,32]. Furthermore, biocides can promote the transfer of resistance genes and, at low concentrations or when misused, act as stressors that do not kill pathogens, potentially causing antimicrobial resistance [30,31]. Resistance mechanisms are particularly concerning in K. pneumoniae, which has become a significant problem in Intensive Care Units, hindering appropriate therapeutic choice due to multiple resistance mechanisms, including carbapenemase production and efflux pumps [26,34]. Similarly, S. aureus remains responsible for several infections, including skin and subcutaneous infections, post-surgical infections, pneumonia, and bacterioma [35,36]. Due to these factors, the importance of mitigating the microorganisms shown in Figure 5 is evident in hospitals, reinforcing the need for preventive measures such as proper hand hygiene and surface disinfection [1]. These findings underscore the need for robust toxicological and microbiological testing, which is examined in the following section. Toxicological and microbiological data gaps A critical limitation identified was the scarcity of toxicological and microbiological validation. Only 34.69% (n = 17) of patents included toxicological testing data. 59.18% (n = 29) reported microbiological tests, primarily focused on bacterial pathogens, with limited evidence of antifungal or antiviral activity. The low frequency of toxicological data in patents compared to scientific literature can be attributed to differences in disclosure requirements. Patent law prioritizes novelty and inventive step over safety validation, which is typically deferred to later regulatory submission stages. Additionally, including toxicological data may narrow patent claims or reveal proprietary testing methods, creating disincentives for disclosure. This gap between patent disclosure and regulatory readiness represents a translational bottleneck that harmonized guidelines could address. Limited testing of formulations against resilient pathogens, such as Candida auris, represents a significant barrier to clinical applicability. Furthermore, the absence of standardized test methods, such as AOAC Use-Dilution or EN ISO 846 A, hinders regulatory approval and cross-comparison between products [37]. This reinforces the need for harmonized global testing guidelines and regulatory science initiatives that integrate sustainability and efficacy requirements [39]. The absence of mechanistic data in nearly 60% of patents has practical consequences that extend beyond academic interest. From a regulatory perspective, disinfectant approval in most jurisdictions requires demonstration of a plausible mechanism of action to assess safety and efficacy. Without this information, applicants face longer review times, additional testing requirements, or outright rejection. For formulation optimization, understanding the mechanism enables rational design for example, combining agents with synergistic mechanisms to reduce effective concentrations and mitigate resistance selection. Most critically, the absence of mechanistic transparency hinders resistance stewardship. Without knowing whether a formulation kills bacteria through a single target (high resistance risk) or multiple targets (lower resistance risk), healthcare providers cannot make informed decisions about product rotation or combination strategies. Sustainability attributes and environmental concerns This subsection reports the sustainability-related claims found in the patents, followed by an analysis of their limitations and environmental implications. It is important to emphasize that sustainability attributes were extracted from patent claims without independent verification. Patent language may prioritize marketing considerations over rigorous environmental testing, meaning that “biodegradable” or “low toxicity” claims may not correspond to validated performance under standardized conditions. Sustainability-related claims were reported in 38.77% of patents. The most frequent claims were: (1) Biodegradability: 24.49% of patents; (2) Plant-based origin: 20.41%; (3) Low toxicity: 16.32%; and (4) Green synthesis methods: 14.28% (Table S3). However, none of the patents employed quantitative environmental metrics, such as carbon footprint or ecological toxicity indices. The predominance of qualitative over quantitative claims limits the value of sustainability reporting for environmental decision-making. The complete absence of quantitative metrics reveals a disconnect between technological development, life-cycle thinking principles, and the circular economy. As discussed in section 3.3, the widespread use of QACs raises persistent environmental and resistance-related concerns. These findings underscore the urgency of transitioning to biodegradable, low-impact alternatives, especially in regions with inadequate wastewater treatment infrastructure [9,10]. Beyond the absence of quantitative metrics, a more fundamental issue is the lack of standardized definitions for sustainability claims in patent documents. Terms such as “biodegradable,” “green,” and “low toxicity” are used without reference to established testing protocols (e.g., OECD 301 for ready biodegradability, ISO 10993 for biocompatibility). This ambiguity creates a “greenwashing” risk, where products may be positioned as environmentally friendly without meeting verifiable criteria. For clinical translation, healthcare procurement committees require comparable, third-party-verified data across different products. Without harmonized reporting standards for patent disclosures, decision-makers cannot reliably distinguish between genuinely sustainable innovations and those making unsubstantiated claims. Future patent guidelines should require references to standardized test methods for any sustainability-related assertion, as is required for efficacy claims, which must reference AOAC or EN ISO standards. To address this gap, future research and patent filings should integrate Life Cycle Assessment (LCA) methodologies (ISO 14040) to evaluate the full environmental impact of disinfectant production, use, and disposal. Technological classes and application diversity The patents encompassed a wide variety of product types, including residual surface disinfectants (24.49%, n = 12), traditional surface disinfectants (20.41%, n = 10), polymer coatings (18.36%, n = 9), hybrid cleaning wipes (14.28%, n = 7), and topical antiseptics (12.24%, n = 6). This diversification indicates a market trend toward multifunctional and convenient delivery systems, such as wipes with optimized release properties. However, few patents incorporated end-of-life considerations, such as packaging recyclability or circular supply chains. This represents an opportunity for future innovations to integrate eco-design principles, reducing the overall environmental footprint of sanitizing products. Policy, regulatory, and industrial implications The findings have direct implications for public policy and industry. The dominance of high-income countries and private corporations suggests that market-driven innovation alone cannot address the global burden of HAIs. Policymakers should prioritize funding mechanisms that support research and innovation in low- and middle-income countries, harmonized regulatory frameworks to streamline approval of sustainable disinfectants, and public-private partnerships to bridge the gap between academic discoveries and market-ready products. From an industrial perspective, companies must move beyond compliance-based strategies to adopt green chemistry principles and transparent reporting of toxicological and environmental data. Early integration of LCA in product development could provide competitive advantages while aligning with international sustainability targets, such as the United Nations Sustainable Development Goals (SDGs). Synthesis and future directions Overall, the current innovation landscape for antimicrobial surface formulations is characterized by emerging but underfunded development of natural and hybrid alternatives, and significant gaps in sustainability assessment (detailed in section 3.6) and toxicological validation (detailed in section 3.5). Bridging these gaps requires a transdisciplinary approach that combines technological foresight, environmental responsibility, and global health equity [14,21,40]. Future research should focus on integrating quantitative environmental metrics in patent documentation, expanding the scope of microbiological testing to include fungi and viruses, and promoting international collaboration to reduce geographic inequities in innovation. By aligning innovation with circular economy principles, stakeholders can accelerate the transition toward cleaner, safer, and more sustainable healthcare environments, ultimately reducing the global burden of HAIs and antimicrobial resistance. The exclusion of Mandarin-language patents is particularly concerning given China’s significant contribution (14.29% of filings), potentially underestimating the full scope of Chinese innovation in this field. Additionally, the exclusive reliance on the Espacenet database, while comprehensive for European and PCT applications, may not fully capture patents from the USPTO or other regional offices, potentially introducing geographic bias. Emerging antimicrobial systems beyond traditional disinfectants The patent search strategy employed in this study, while systematic, was intentionally restricted to IPC codes A01N33/12 (QACs) and A01P1/00 (non-therapeutic antimicrobials). Consequently, emerging material-based antimicrobial systems that may not be captured by these classifications,such as gallium- and silver-gallium-based platforms, were not represented in our dataset. However, their growing presence in the scientific literature warrants discussion as they address many of the sustainability and resistance limitations highlighted in this review. Gallium-based antimicrobial systems operate through a fundamentally different mechanism than conventional disinfectants. Rather than relying on membrane disruption or oxidative damage, gallium mimics iron and disrupts bacterial iron metabolism, interfering with Fe-S cluster function and essential enzymatic processes [43,44]. When combined with silver, these systems can provide controlled ion release and potent antimicrobial activity while maintaining better biocompatibility and lower ecotoxicity than many synthetic biocides [43–46]. A recent patent application describes a method for preparing silver-gallium compositions with potential applications in surface disinfection [46]. Although such systems are not yet widely represented in the patent landscape for healthcare surface disinfectants, their emergence signals a possible shift toward metabolism-targeting, resistance-agnostic antimicrobial strategies. Future patent-based reviews should expand their IPC coverage to include material science classifications (e.g., C22C, B82Y) to capture these innovations and provide a more complete picture of the field’s direction. Table 2 presents representative examples by compound type, mechanism of action, microbial target, and sustainability features. Table 2.Representative patented antimicrobial formulations detailing compound type, mechanism of action, spectrum of targeted microorganisms, and associated sustainability claims.Patent ID (example)Compound typeMechanism of actionTarget microorganismsSustainability claimUS2024172755A1Nanoparticles (Porphyrin)ROS generationBacteria, FungiGreen synthesis, biodegradableCA3232534A1QACs + AlcoholsProtein denaturationBroad-spectrum including sporesWipe format with optimized releaseEP2964208A1Phenolic CompoundsMembrane destabilizationBacteria, Fungi, InsectsLow toxicity, botanical originCN102845512AChitosan + Tea Tree OilMembrane disruptionS. aureus, E. coliBiodegradable, natural originUS2012157540A1Biguanides (PHMB)Enzyme inhibitionBacteria, Fungi, Viruses (enveloped)Safe, low environmental impactLegend: E. coli—Escherichia coli; QACs—Quaternary Ammonium Compounds; ROS—Reactive Oxygen Species; S. aureus—Staphylococcus aureus.In parallel, Table 3 provides a broader cross-sectional analysis of the 49 reviewed patents, categorizing them by chemical composition and intended technological application. Representative patented antimicrobial formulations detailing compound type, mechanism of action, spectrum of targeted microorganisms, and associated sustainability claims. Legend: E. coli—Escherichia coli; QACs—Quaternary Ammonium Compounds; ROS—Reactive Oxygen Species; S. aureus—Staphylococcus aureus.In parallel, Table 3 provides a broader cross-sectional analysis of the 49 reviewed patents, categorizing them by chemical composition and intended technological application. In parallel, Table 3 provides a broader cross-sectional analysis of the 49 reviewed patents, categorizing them by chemical composition and intended technological application. Table 3.Categorization of antimicrobial patent formulations by compound type and technological class.Compound typeResidual surface disinfectantsTraditional surface disinfectantsTopical antisepticsInsertable components for formulationsOther (e.g., polymer coatings)Quaternary Ammonium Compounds45033Biguanides31352Metallic Nanoparticles40042Phenolic Compounds10151Essential Oils50143Biosurfactants03502Chitosan Derivatives30135Hybrid Formulations (Synthetic + Natural)33011Halophenols10243Peroxides32420Values represent the number of patents employing each compound category in the application. Categorization of antimicrobial patent formulations by compound type and technological class. Values represent the number of patents employing each compound category in the application. The findings also highlight the importance of global equity in innovation. Greater support for research and development in low- and middle-income countries could address local sanitation challenges and diversify the innovation ecosystem, fostering culturally and ecologically tailored solutions for infection control. Expert opinion/commentary Healthcare environments require surface disinfection strategies that are not only effective against high-priority pathogens but also compatible with long-term occupational safety and environmental sustainability. The patent landscape mapped here suggests that innovation in antimicrobial surface formulations has accelerated since 2015, yet it remains largely centered on well-established synthetic chemistries, particularly quaternary ammonium compounds. This concentration is understandable given their broad range of activities and manufacturing maturity. Still, it reinforces a “lock-in” effect: incremental innovations dominate, while fewer solutions address emerging requirements such as greener life cycles, reduced ecotoxicity, and resistance-aware stewardship. A notable finding is the low frequency with which patents report mechanisms of action and toxicological evidence. From a translational standpoint, this is a critical bottleneck. For products intended for routine use in healthcare settings, regulatory and procurement decisions increasingly depend on documented safety (acute and chronic toxicity, sensitization, inhalation exposure risk), environmental fate (biodegradability, persistence, aquatic toxicity), and performance under realistic conditions (presence of organic load, repeated application, compatibility with diverse materials). When these data are absent or not at least anticipated in the development plan, the path from protected invention to scalable adoption becomes longer, more expensive, and more uncertain. The limited share of patents incorporating natural or hybrid actives indicates both opportunity and risk. Natural compounds may improve sustainability narratives, but “natural” is not synonymous with “safe” or “effective” at practical concentrations, and compositional variability can complicate quality control. Hybrid approaches, combining established disinfectant backbones with bio-based components, slow-release matrices, or surface-binding strategies, appear promising because they can balance efficacy with reduced dosing, lower exposure, and improved durability. However, hybrid designs must be supported by rigorous toxicological profiling and realistic-use testing; otherwise, they risk being positioned as “green” without meeting the evidentiary bar required for healthcare procurement. In the next five to ten years, competitive advantage in this domain will likely shift from simply introducing new actives toward delivering integrated product dossiers: (i) validated antimicrobial performance against priority organisms (including MDR strains and biofilms where relevant), (ii) clear mechanistic rationale to support claims and mitigate resistance concerns, (iii) comprehensive toxicology aligned with intended exposure scenarios, and (iv) life-cycle assessment embedded early in R&D to reduce downstream reformulation. Harmonized regulatory guidance for environmental claims and standardized test batteries for “sustainable disinfectants” would reduce uncertainty for innovators and purchasers, accelerating adoption of genuinely safer alternatives. Finally, the dominance of private applicants suggests strong market interest, but also underscores the need for public-sector leadership. Public policies that incentivize safer-by-design chemistry, transparent reporting of safety and environmental endpoints, and structured public–private partnerships can bridge the gap between inventive activity and implementation at scale. Without these mechanisms, the field risks continuing to generate patents faster than it generates deployable, trusted solutions for infection prevention worldwide. Conclusion This study presents a global landscape analysis of antimicrobial surface disinfectants based on patent data, revealing an active and evolving field that is increasingly responsive to microbial threats and sustainability imperatives. The results indicate that while synthetic agents such as quaternary ammonium compounds continue to dominate the technological space, a notable shift is occurring toward hybrid and nature-based alternatives that offer improved environmental profiles. The predominance of patents filed by industry players in high-income countries reflects market priorities and research infrastructure asymmetries. However, the limited representation from emerging economies underscores the need for greater international cooperation, funding, and policy frameworks that enable inclusive innovation. Bridging these regional disparities could foster the development of cost-effective, locally adapted solutions to combat healthcare-associated infections. Critical gaps remain in the experimental substantiation of patented technologies. The scarcity of toxicological and mechanistic data limits the readiness of many formulations for regulatory approval and widespread adoption. A key finding of this review is the complete absence of quantitative environmental metrics (e.g., LCA, carbon footprint) in all analyzed patents, highlighting a critical gap between sustainability claims and verifiable data. For innovation to translate into practice, especially in high-risk hospital environments, future efforts must emphasize thorough validation, lifecycle analysis, and alignment with sustainable development targets. In conclusion, integrating technological foresight, environmental responsibility, and global health equity should guide the next generation of disinfectant technologies. Patent-based surveillance is valuable for identifying promising trends and strategic opportunities, supporting cleaner production systems and safer healthcare environments worldwide. Future studies should prioritize (i) expanding patent searches to include a broader range of IPC codes and multilingual databases (e.g., Chinese and German) to reduce language and classification biases; (ii) developing standardized, quantitative sustainability metrics (e.g., carbon footprint, ecotoxicity indices) for disinfectant formulations; (iii) incorporating systematic toxicological and mechanistic data into patent filings to accelerate regulatory approval; and (iv) fostering international public–private partnerships to translate academic innovations into scalable, market-ready products, particularly in low- and middle-income countries where the burden of HAIs is highest. Future perspective Over the next 5–10 years, the competition in antimicrobial surface engineering will likely shift from incremental improvements of synthetic biocides toward “safer-by-design” platforms. We anticipate the emergence of metabolism-targeting systems, such as gallium and silver-gallium hybrid materials, which offer resistance-agnostic mechanisms and lower ecotoxicity. Furthermore, the integration of quantitative sustainability metrics, such as Life Cycle Assessment (LCA) and carbon footprinting, will become a mandatory standard for healthcare procurement, pushing the industry toward verified green chemistry. Standardized global testing protocols (AOAC/ISO) for sustainable disinfectants will be essential to reduce the current translational bottleneck between patenting and clinical implementation, especially in low- and middle-income countries. Supplementary Material Supplemental Material Funding Statement This article was not funded. This research was supported by the Federal University of Bahia and CAPES/CNPq. Author contributions Conceptualization: LC Nunes, ECL Cazedey; Methodology: LC Nunes, SS Santos, IA Alves; Formal analysis: LC Nunes, SS Santos; Data Curation: LC Nunes, SS Santos; Writing—Original Draft: LC Nunes; Writing—Review & Editing: IA Alves, ECL Cazedey, L Rossato; Supervision: ECL Cazedey. All authors have read and agreed to the published version of the manuscript. Disclosure statement The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. Geolocation information Faculty of Pharmacy, Federal University of Bahia, Salvador, Bahia, Brazil. References Papers of special note have been highlighted as either of interest (*) or of considerable interest (**) to readers. Associated Data Supplementary Materials Supplemental Material